News & Events

January 17, 2019

Ablexis Announces Expansion of Non-Exclusive Perpetual License Agreement with Eli Lilly and Company / READ MORE

January 3, 2019

Ablexis Announces Licensing Agreement with Corvidia Therapeutics / READ MORE

December 6, 2018

Ablexis Announces Licensing Agreement with Allogene Therapeutics / READ MORE

November 13, 2018

Ablexis Announces Progress in Its Intellectual Property on AlivaMab Mouse and Immunoglobulin Locus Engineering / READ MORE

November 5, 2018

Ablexis Announces Antibody Discovered Using AlivaMab Mouse Platform Enters Clinical Development / READ MORE

October 23, 2018

Ablexis Announces Licensing Agreement with Voyager Therapeutics / READ MORE

October 9, 2018

Ablexis Announces Licensing Agreement with Memorial Sloan Kettering Cancer Center / READ MORE

June 21, 2018

Ablexis Targets Market Expansion Opportunities for AlivaMab Mouse Following Acquisition by Deerfield Management and the Founding of AlivaMab Discovery Services / READ MORE

Conferences

Biocom Global Life Science Partnering Conference

February 26 - February 28, 2019
La Jolla, CA

Bio Asia

March 5 - March 6, 2019
Tokyo, Japan

PEGS 2019

April 8 - April 12, 2019
Boston, MA

On-demand Webinars

Begin with the End in Mind: Selection of an Antibody Discovery Platform

How the choice of therapeutic antibody discovery platform can impact downstream success in development and the market

Register